
Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has won the CPHI & PMEC India Award in the category R&D Excellence. The recognition highlights Dr. Reddy’s pioneering work developing a continuous API manufacturing process. This includes the successful implementation of flow chemistry and the end-to- end continuous manufacturing of a drug substance at a commercial scale of approximately 300 kg API/day. This innovative process is significantly faster than the traditional batch-to-batch method, with three chemical conversions now happening in less than two minutes, compared to hours in the batch process.
Commenting on the recognition, Deepak Sapra, Head of API and Services, said, “At Dr. Reddy’s, our focus is on accelerating access, advancing cutting-edge science, and promoting sustainability. Transitioning from batch-to-batch API manufacturing to continuous manufacturing provides significant benefits. It enables us to scale production to meet patient demand while reducing our environmental impact through a greener approach. This award is a testament to the dedication of our R&D team and highlights our commitment to investing in science and technology, nurturing talented scientists, and fostering innovation in product development.”
本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。